If these meetings and conferences are generating partnerships, lifting the IND, or driving value — then great. But where is the outcome? What has been achieved? How is this creating shareholder value right now?I've never seen a partnership or funding announced, until it's announced. I don't expect the company to divulge who they have been speaking to or where a potential deal may be at - that just doesn't happen in business, until it happens! As for getting out and about regardless - how else do they attract attention? Just sit at home and wait for somebody to come knocking?
To make matters more confusing, when the FDA placed the IND on clinical hold, the company immediately commenced trials to address issues — before even receiving written feedback from the FDA. That raises a legitimate question - Did the company already know what the FDA would object to?If so, was that information ignored in the initial submission?Was it a strategic misjudgment — betting that human data could override preclinical concerns — or something else?As the company announced, they were in discussion with the FDA following the clinical hold, so being proactive and not wanting to waste time, they got on with what they understand the FDA now want to see. As of yet, no formal communication detailing that has come from the FDA. Had management not started when they did, we would all be waiting a lot longer. As for any information being 'ignored' - our submission was reviewed by the SAB, Healy and management - and everybody approved of its submission. There may have been a professional judgement made about data adequacy, but if that was highlighted before the submission we'd be in the same boat anyway - waiting for further trials to complete to submit said data.
As for those suggesting I should keep my comments off LinkedIn — I respectfully disagree. Holding management accountable in public, where reputation matters, makes them work harder. Companies love to use LinkedIn when it suits them. Shareholders should feel free to use it too — especially when the ASX isn’t doing much to enforce standards in the small-cap space.At the end of the day, I want Neurizon to succeed — like every shareholder here. But that means demanding transparency, discipline, and performance, not applauding plane tickets and PowerPoint slides.Sound like a bit of self-importance to me. Have you made any attempt to discuss any of those matters directly with the CEO? I know you haven't or these questions would be answered. I can tell you now - MT is NOT hard to get hold of and is willing to discuss matters with anybody that directly asks questions.
I sincerely hope that positive news is on the horizon....It is - I can feel it in me waters!
(20min delay)